805.93
price up icon0.30%   2.45
after-market Dopo l'orario di chiusura: 805.93
loading
Precedente Chiudi:
$803.48
Aprire:
$801.76
Volume 24 ore:
541.27K
Relative Volume:
0.56
Capitalizzazione di mercato:
$82.97B
Reddito:
$14.92B
Utile/perdita netta:
$4.42B
Rapporto P/E:
19.64
EPS:
41.0422
Flusso di cassa netto:
$3.79B
1 W Prestazione:
-0.26%
1M Prestazione:
+19.10%
6M Prestazione:
+1.56%
1 anno Prestazione:
+38.86%
Intervallo 1D:
Value
$795.73
$813.18
Intervallo di 1 settimana:
Value
$784.61
$815.80
Portata 52W:
Value
$541.00
$821.11

Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile

Name
Nome
Regeneron Pharmaceuticals Inc
Name
Telefono
(914) 847-7000
Name
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Name
Dipendente
15,410
Name
Cinguettio
@regeneron
Name
Prossima data di guadagno
2026-07-30
Name
Ultimi documenti SEC
Name
REGN's Discussions on Twitter

Compare REGN vs VRTX, ARGX, RVMD, ONC

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
REGN icon
REGN
Regeneron Pharmaceuticals Inc
805.93 82.72B 14.92B 4.42B 3.79B 41.04
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
515.55 128.19B 12.34B 4.34B 3.71B 16.87
ARGX icon
ARGX
Argen X Se Adr
987.84 53.26B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
212.00 43.66B 742.00K -1.37B -1.07B -7.0731
ONC icon
ONC
Beone Medicines Ltd Adr
362.51 39.31B 5.76B 514.49M 1.10B 4.4813

Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2026-03-31 Ripresa Piper Sandler Overweight
2026-03-06 Iniziato Barclays Overweight
2026-01-07 Aggiornamento BofA Securities Underperform → Buy
2025-12-03 Downgrade Morgan Stanley Overweight → Equal-Weight
2025-11-24 Iniziato HSBC Securities Buy
2025-11-24 Ripresa Truist Buy
2025-11-13 Iniziato Scotiabank Sector Perform
2025-08-14 Iniziato Rothschild & Co Redburn Buy
2025-06-30 Downgrade Argus Buy → Hold
2025-05-30 Downgrade RBC Capital Mkts Outperform → Sector Perform
2025-05-30 Downgrade Wells Fargo Overweight → Equal Weight
2025-05-14 Aggiornamento Citigroup Neutral → Buy
2025-04-22 Ripresa Cantor Fitzgerald Overweight
2025-02-05 Aggiornamento Leerink Partners Market Perform → Outperform
2025-01-16 Downgrade UBS Buy → Neutral
2024-12-10 Ripresa BofA Securities Underperform
2024-11-15 Iniziato Wolfe Research Outperform
2024-11-14 Iniziato Citigroup Neutral
2024-09-24 Downgrade Leerink Partners Outperform → Market Perform
2024-03-12 Iniziato Bernstein Outperform
2024-01-12 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2023-11-09 Iniziato Deutsche Bank Hold
2023-11-03 Aggiornamento Raymond James Mkt Perform → Outperform
2023-08-21 Aggiornamento Canaccord Genuity Hold → Buy
2023-08-21 Reiterato Oppenheimer Perform
2023-06-28 Downgrade Canaccord Genuity Buy → Hold
2023-03-27 Aggiornamento SVB Securities Market Perform → Outperform
2023-03-24 Aggiornamento Jefferies Hold → Buy
2023-03-23 Aggiornamento Raymond James Underperform → Mkt Perform
2023-01-30 Aggiornamento Cowen Market Perform → Outperform
2023-01-20 Aggiornamento JP Morgan Neutral → Overweight
2022-10-26 Downgrade Raymond James Mkt Perform → Underperform
2022-10-17 Downgrade Evercore ISI Outperform → In-line
2022-09-09 Aggiornamento Jefferies Underperform → Hold
2022-09-09 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2022-07-25 Downgrade SVB Leerink Outperform → Mkt Perform
2022-07-13 Iniziato Cantor Fitzgerald Neutral
2022-06-06 Iniziato Jefferies Underperform
2022-05-23 Iniziato SVB Leerink Outperform
2022-01-05 Downgrade BofA Securities Neutral → Underperform
2022-01-03 Aggiornamento Bernstein Mkt Perform → Outperform
2021-12-15 Downgrade Bernstein Outperform → Mkt Perform
2021-12-09 Ripresa Wells Fargo Overweight
2021-12-07 Ripresa Cowen Market Perform
2021-12-06 Iniziato Goldman Buy
2021-11-19 Ripresa BMO Capital Markets Outperform
2021-11-05 Downgrade The Benchmark Company Buy → Hold
2021-06-29 Iniziato H.C. Wainwright Buy
2021-01-25 Aggiornamento BMO Capital Markets Market Perform → Outperform
2021-01-13 Aggiornamento The Benchmark Company Hold → Buy
2021-01-08 Aggiornamento Citigroup Neutral → Buy
2020-10-05 Aggiornamento Cantor Fitzgerald Neutral → Overweight
2020-08-20 Downgrade The Benchmark Company Buy → Hold
2020-07-09 Aggiornamento SunTrust Hold → Buy
2020-05-26 Aggiornamento Wells Fargo Equal Weight → Overweight
2020-04-28 Downgrade Citigroup Buy → Neutral
2020-04-17 Aggiornamento The Benchmark Company Hold → Buy
2020-04-08 Iniziato The Benchmark Company Hold
2020-03-31 Iniziato Wolfe Research Peer Perform
2020-02-27 Iniziato Barclays Overweight
2020-02-26 Aggiornamento Canaccord Genuity Hold → Buy
2020-02-26 Downgrade Robert W. Baird Outperform → Neutral
2020-02-25 Aggiornamento Jefferies Hold → Buy
2020-02-11 Aggiornamento Argus Hold → Buy
2019-12-24 Iniziato Raymond James Mkt Perform
2019-12-16 Downgrade Evercore ISI Outperform → In-line
2019-12-13 Aggiornamento Credit Suisse Neutral → Outperform
2019-11-12 Iniziato SunTrust Hold
2019-11-07 Aggiornamento Citigroup Neutral → Buy
2019-10-17 Ripresa BofA/Merrill Neutral
2019-09-23 Aggiornamento Guggenheim Neutral → Buy
Mostra tutto

Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie

pulisher
04:39 AM

Resilient Regeneron stock hovers near 52-week high after dividend and analyst target hike - AD HOC NEWS

04:39 AM
pulisher
12:26 PM

REGN UPCOMING DEADLINE: Levi & Korsinsky Alerts Regeneron - globenewswire.com

12:26 PM
pulisher
12:10 PM

Biotech Stocks To ResearchAugust 17th - MarketBeat

12:10 PM
pulisher
10:42 AM

Can Regeneron Pharmaceuticals (NASDAQ:REGN) Extend Its Run? - Kalkine Media

10:42 AM
pulisher
10:16 AM

REGN Investors Have Opportunity to Lead Regeneron - globenewswire.com

10:16 AM
pulisher
09:19 AM

REGN Maintained by Leerink Partners -- Price Target Raised to $8 - GuruFocus

09:19 AM
pulisher
08:49 AM

Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $824.00 at Leerink Partners - MarketBeat

08:49 AM
pulisher
06:37 AM

Leerink Partners Adjusts PT on Regeneron Pharmaceuticals to $824 From $641, Maintains Market Perform Rating - marketscreener.com

06:37 AM
pulisher
06:34 AM

Plato Investment Management Ltd Makes New $2.47 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

06:34 AM
pulisher
05:36 AM

Oppenheimer Asset Management Inc. Takes $1.50 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

05:36 AM
pulisher
04:04 AM

Focus Partners Advisor Solutions LLC Invests $1.35 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

04:04 AM
pulisher
03:38 AM

AMG National Trust Bank Makes New $1.22 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

03:38 AM
pulisher
Aug 16, 2026

Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - mykxlg.com

Aug 16, 2026
pulisher
Aug 16, 2026

REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review

Aug 16, 2026
pulisher
Aug 16, 2026

USA Financial Formulas Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Aug 16, 2026
pulisher
Aug 15, 2026

ETFs Investing in Regeneron Pharmaceuticals, Inc. Stocks - TradingView

Aug 15, 2026
pulisher
Aug 15, 2026

7,506 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Summit Global Investments - MarketBeat

Aug 15, 2026
pulisher
Aug 15, 2026

How Securities Lawsuits Over Trial Disclosures Will Impact Regeneron Pharmaceuticals’ (REGN) Pipeline-Driven Investment Story - simplywall.st

Aug 15, 2026
pulisher
Aug 15, 2026

Wall Street Zen Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Strong-Buy - MarketBeat

Aug 15, 2026
pulisher
Aug 14, 2026

REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Aug 14, 2026
pulisher
Aug 14, 2026

GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk) - The Motley Fool

Aug 14, 2026
pulisher
Aug 14, 2026

Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline? - finance.yahoo.com

Aug 14, 2026
pulisher
Aug 14, 2026

Bernstein Lifts Regeneron Price Target to $756, Stays on Sidelines - finance.biggo.com

Aug 14, 2026
pulisher
Aug 14, 2026

If You Invested $1000 In Regeneron Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today - Benzinga

Aug 14, 2026
pulisher
Aug 14, 2026

Regeneron Genetics Center's Andy Deubler: The AI-Era Genomics Race Will Be Decided by Curation, Not Volume - finance.biggo.com

Aug 14, 2026
pulisher
Aug 14, 2026

The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class ... - Caledonian Record

Aug 14, 2026
pulisher
Aug 14, 2026

BMS builds big in Texas; Regeneron backs would-be rival - Pharma Voice

Aug 14, 2026
pulisher
Aug 14, 2026

Bernstein raises Regeneron stock price target to $756 on Eylea beat - Investing.com Canada

Aug 14, 2026
pulisher
Aug 14, 2026

Bernstein Adjusts PT on Regeneron Pharmaceuticals to $756 From $753, Maintains Market Perform Rating - marketscreener.com

Aug 14, 2026
pulisher
Aug 14, 2026

Regeneron's Gene Therapy For Genetic Hearing Loss Gets Accelerated FDA Nod — Drug Pricing Deal With White House To Be Announced Today - Stocktwits

Aug 14, 2026
pulisher
Aug 14, 2026

Regeneron Pharmaceuticals, Inc. (REGN) Investors: September 14, 2026 Lead Plaintiff Deadline in Class Action LawsuitHagens Berman - ycharts.com

Aug 14, 2026
pulisher
Aug 13, 2026

REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Aug 13, 2026
pulisher
Aug 13, 2026

Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Aug 13, 2026
pulisher
Aug 13, 2026

REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action LawsuitInvestors Should Contact SueWallSt - Morningstar

Aug 13, 2026
pulisher
Aug 13, 2026

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm - lincolnjournal.com

Aug 13, 2026
pulisher
Aug 13, 2026

Regeneron Pharmaceuticals, Inc. (REGN) Stock Price, News, Quote & History - Yahoo Finance

Aug 13, 2026
pulisher
Aug 13, 2026

Parabilis Medicines Advances Zolucatetide Toward Phase 3 in Desmoid Tumors, Announces Regeneron Collaboration and $1.1 Billion Cash Position - Quiver Quantitative

Aug 13, 2026
pulisher
Aug 12, 2026

Regeneron Director Kathryn Guarini Executes 400 Stock Options and Sells Shares Under Rule 10b5-1 Plan - Kalkine Media

Aug 12, 2026
pulisher
Aug 12, 2026

Regeneron Director Huda Y. Zoghbi Executes Stock Option and Sells Shares on August 10, 2026 - Kalkine Media

Aug 12, 2026
pulisher
Aug 12, 2026

Insider Selling: Regeneron Pharmaceuticals (NASDAQ:REGN) Director Sells $320,000.00 in Stock - MarketBeat

Aug 12, 2026
pulisher
Aug 12, 2026

Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action LawsuitHagens Berman Sobol Shapiro LLP - PR Newswire

Aug 12, 2026
pulisher
Aug 12, 2026

REGN Stockholders May Be Entitled to Lead the Class Action - globenewswire.com

Aug 12, 2026
pulisher
Aug 12, 2026

Bronstein, Gewirtz & Grossman LLC Urges Regeneron - GlobeNewswire

Aug 12, 2026
pulisher
Aug 12, 2026

REGN DEADLINE: Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. Investors of Upcoming Securities Class Action Deadline - PR Newswire

Aug 12, 2026
pulisher
Aug 12, 2026

REGENERNON PHARMACEUTICALS, INC. INVESTORS WITH LOSSES HAVE - globenewswire.com

Aug 12, 2026
pulisher
Aug 12, 2026

REGN Looks 7.8% Undervalued on GF Value™ Amid Strong Market Position - GuruFocus

Aug 12, 2026
pulisher
Aug 12, 2026

Wedge Capital Management L L P NC Purchases 8,063 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Aug 12, 2026
pulisher
Aug 12, 2026

Insight Wealth Strategies LLC Has $5.46 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Aug 12, 2026
pulisher
Aug 12, 2026

Regeneron, Tenet leads top healthcare companies with highest earnings beats (XLV:NYSEARCA) - Seeking Alpha

Aug 12, 2026
pulisher
Aug 12, 2026

How Regeneron Pharmaceuticals Went From Cheaper Than Incyte To The Pricier Stock - Trefis

Aug 12, 2026
pulisher
Aug 12, 2026

Handelsbanken Fonder AB Trims Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Aug 12, 2026

Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Regeneron Pharmaceuticals Inc Azioni (REGN) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Guarini Kathryn
Director
Aug 10 '26
Sale
800.00
400
320,000
603
Zoghbi Huda Y
Director
Aug 10 '26
Option Exercise
376.69
800
301,352
2,503
Zoghbi Huda Y
Director
Aug 10 '26
Sale
800.00
800
640,000
1,703
$987.84
price up icon 16.04%
$212.00
price up icon 4.07%
ONC ONC
$362.51
price up icon 4.33%
$515.55
price up icon 1.94%
$224.60
price down icon 1.77%
Capitalizzazione:     |  Volume (24 ore):